广告招募

8-OHdG抗体说明书

2025年11月25日 10:52:52      来源:上海劲马实验设备有限公司 >> 进入该公司展台      阅读量:5

分享:

 

 在生命科学试剂方面,我们代理诸多欧美等:sigma,amresco,bachem,abcam,merck,millipore,abgent, Chemicon, R&D, BD,bender,biovision,ENZO,CST, Biosource, Life Technologies,Fitzgerald, Biodesign, serotec, Biolegend,Fermentas,Qiagen,signagen等。我们密切国内外的科研进展,为您提供高质量的产品和专业的服务!
您对产品有任何问题,可以通过,,与我们公司,我们确保您在zui短时间内得到满意的回复。我们将不断提供新产品和新技术资料,并将借助网络平台,以让您能够认识我们公司,了解我们的产品,获得。
本公司: :  何
 


BACKGROUND
DNA or RNA damage can hinder the ability of a cell to carry out its function and can significantly increase the likelihood of tumor formation. One of the causes of damaged DNA and RNA is oxidation of the bases. 8­hydroxy­2'­deoxyguanosine, 8­hydroxyguanine (8­OHdG) and 8­hydroxyguanosine are all markers of oxidative damage to RNA and DNA. 8­hydroxy­2'­deoxyguanosine is produced by reactive oxygen and nitrogen species, including hydroxyl radi­cal and peroxynitrite. 8­hydroxyguanine is one of the major base lesions involved in mutagenesis and is caused by ionizing radiation and radiomimetic agents. 8­hydroxy­guanosine induces a transversion of G to T in DNA, which may be mutagenic. Markers of DNA and RNA damage are useful research tools when studying the effects of this type of damage.
 
 
REFERENCES
1. Musarrat, J., et al. 1996. Prognostic and aetiological relevance of 8­hydroxyguanosine in human breast carcinogenesis. Eur. J. Cancer 32: 1209­1214
2. Parker, A.R., et al. 2002. 8­hydroxyguanosine repair is defective in some microsalite stable colorectal cancer cells. Cancer Res. 62: 7230­7233.
3. Abe, T., et al. 2002. Alteration of 8­hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinsons disease. Neurosci. Lett. 336: 105­108.
4. Winter, D.B., et al. 2003. Normal somatic hypermutation of Ig genes in the absence of 8­hydroxyguanine­DNA glycosylase. J. Immunol. 170: 5558­5562.
5. Russo, M.T., et al. 2004. Accumulation of the oxidative base lesion 8­hydroxyguanine in DNA of tumor­prone mice defective in both the MYH and OGG1 DNA glycosylases. Cancer Res. 64: 4411­4414.
6. Okugawa, Y., et al. 2006. UVA­induced degradation of 8­hydroxyguanine in oligonucleotide and the effect on its activities in yeast oligonucleotide transformation assay. Nucleic Acids Symp. Ser. 48: 287­288.
7. Watanabe, E., et al. 2006. Significance of 8­hydroxy­2'­deoxyguanosine levels in patients with idiopathic dilated cardiomyopathy. J. Card. Fail. 12: 527­532.
8. Noblitt, S.D., et al. 2007. The role of metal ion binding in generating 8­hydroxy­2'­deoxyguanosine from the nucleoside 2'­deoxyguanosine and the nucleotide 2'­deoxyguanosine­5'­monophosphate. J. Inorg. Biochem.
101: 536­542.
9. Kuo, H.W., et al. 2007. Urinary 8­hydroxy­2'­deoxyguanosine (8­OHdG) and genetic polymorphisms in breast cancer patients. Mutat. Res. 631: 62­68.
 
 
 
APPLICATIONS
8­OHdG (J­1) is recommended for detection of 8­OHdG modified proteins by Western Blotting (starting dilution 1:200, dilution range 1:100­1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50­1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30­1:3000).
 
 
RESEARCH USE
For research use only, not for use in diagnostic procedures.
 
 
RECOMMENDED SECONDARY REAGENTS
To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti­rabbit IgG­HRP: sc­2004 (dilution range: 1:2000­1:100,000) or Cruz Marker compatible goat anti­rabbit IgG­HRP: sc­2030 (dilution range: 1:2000­1:5000), Cruz Marker Molecular Weight Standards: sc­2035, TBS Blotto A Blocking Reagent: sc­2333 and Western Blotting Luminol Reagent: sc­2048. 2) Immunofluo­rescence: use goat anti­rabbit IgG­FITC: sc­2012 (dilution range: 1:100­1:400) or goat anti­rabbit IgG­TR: sc­2780 (dilution range: 1:100­1:400) with UltraCruz Mounting Medium: sc­24941.
 
 
版权与免责声明:
1.凡本网注明"来源:全球供应商网"的所有作品,版权均属于全球供应商网,转载请必须注明全球供应商网。违反者本网将追究相关法律责任。
2.企业发布的公司新闻、技术文章、资料下载等内容,如涉及侵权、违规遭投诉的,一律由发布企业自行承担责任,本网有权删除内容并追溯责任。
3.本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。 4.如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系。